1. Lack of Synergy Between β-Agonist Treatment and a Blockage of Sarcoplasmic Calcium Flow in a Rat Cancer Cachexia Model
   Silvia Busquets et al, 2021, OncoTargets and Therapy CrossRef
2. Erythropoietin improves cardiac wasting and outcomes in a rat model of liver cancer cachexia
   Masakazu Saitoh et al, 2016, International Journal of Cardiology CrossRef
3. A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy
   Míriam Toledo et al, 2016, Journal of Cachexia, Sarcopenia and Muscle CrossRef
4. Immobilization in diabetic rats results in altered glucose tolerance A model of reduced locomotion/activity in diabetes
   Enrica Marmonti et al, 2018, JCSM Rapid Communications CrossRef
5. Differential structural features in soleus and gastrocnemius of carnitine‐treated cancer cachectic rats
   Sílvia Busquets et al, 2020, Journal of Cellular Physiology CrossRef
6. β2-Adrenergic agonists and the treatment of skeletal muscle wasting disorders
   Olivier R. Joassard et al, 2013, The International Journal of Biochemistry & Cell Biology CrossRef
7. Counteracting Muscle Atrophy on Earth and in Space via Nanofluidics Delivery of Formoterol
   Andrea Ballerini et al, 2020, Advanced Therapeutics CrossRef
8. Cancer-induced muscle wasting: latest findings in prevention and treatment
   Zaira Aversa et al, 2017, Therapeutic Advances in Medical Oncology CrossRef
9. Formoterol attenuates increased oxidative stress and myosin protein loss in respiratory and limb muscles of cancer cachectic rats
   Anna Salazar-Degracia et al, 2017, PeerJ CrossRef
10. Formoterol reduces muscle wasting in mice undergoing doxorubicin chemotherapy
    Edson Alves de Lima Junior et al, 2024, Frontiers in Oncology CrossRef
11. Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β‐2 agonist
    Míriam Toledo et al, 2016, International Journal of Cancer CrossRef
12. From Target Identification to Drug Development in Space: Using the Microgravity Assist
    Martin Braddock, 2020, Current Drug Discovery Technologies CrossRef
13. Unraveling the lost balance: Adrenergic dysfunction in cancer cachexia
    Parham Diba et al, 2024, Autonomic Neuroscience CrossRef
14. Phenotypic features of cancer cachexia‐related loss of skeletal muscle mass and function: lessons from human and animal studies
    Agnès Martin et al, 2021, Journal of Cachexia, Sarcopenia and Muscle CrossRef
15. Pharmaceutical Agents for Contractile-Metabolic Dysfunction After Volumetric Muscle Loss
    Jennifer McFaline-Figueroa et al, 2022, Tissue Engineering Part A CrossRef
16. Effects of the beta 2 agonist formoterol on atrophy signaling, autophagy, and muscle phenotype in respiratory and limb muscles of rats with cancer-induced cachexia
    Anna Salazar-Degracia et al, 2018, Biochimie CrossRef